$ORKA News

Oruka Therapeutics Is Priced For Perfection - It's Time To Cash Out

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

Oruka Therapeutics - Intriguing Long Acting Psoriasis Programs May Need Further Derisking

Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares

UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130

Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Oruka Therapeutics Expands ORKA-001 License To All Indications, Adding Future IBD Rights Under Paragon Amendment

An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

Oruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh Funding

BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Oruka Therapeutics Q1 EPS $(0.48) Beats $(0.55) Estimate